@sidoniaf.bsky.social
Reposted
Muramatsu had previously reported the discovery of the AID gene in a screen. In the 2000 Cell paper, he and his collaborators in the Honjo lab, including Fagarasan demonstrated its function in mice.
www.cell.com/AJHG/fulltex...
www.cell.com/AJHG/fulltex...
Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme
Induced overexpression of AID in CH12F3-2 B lymphoma cells augmented class switching
from IgM to IgA without cytokine stimulation. AID deficiency caused a complete defect
in class switching and showed...
www.cell.com
December 15, 2025 at 6:10 AM
Muramatsu had previously reported the discovery of the AID gene in a screen. In the 2000 Cell paper, he and his collaborators in the Honjo lab, including Fagarasan demonstrated its function in mice.
www.cell.com/AJHG/fulltex...
www.cell.com/AJHG/fulltex...
Reposted
In the same issue, Revy, Fischer and Durandy showed that the same gene, AID, was responsible for a mysterious form of hyper-IgM syndrome that was not linked to mutations in the CD40 pathway, demonstrating that AID also controlled CSR and SHM in humans.
www.cell.com/fulltext/S00...
www.cell.com/fulltext/S00...
Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2)
The activation-induced cytidine deaminase (AID) gene, specifically expressed in germinal
center B cells in mice, is a member of the cytidine deaminase family. We herein report
mutations in the human c...
www.cell.com
December 15, 2025 at 6:12 AM
In the same issue, Revy, Fischer and Durandy showed that the same gene, AID, was responsible for a mysterious form of hyper-IgM syndrome that was not linked to mutations in the CD40 pathway, demonstrating that AID also controlled CSR and SHM in humans.
www.cell.com/fulltext/S00...
www.cell.com/fulltext/S00...
Reposted
Prof Tasuku Honjo is now the Director of CCII, our new center in Kyoto University, dedicated to deciphering anti-tumor immunity and discovering the next generation of cancer immunotherapies.
www.ccii.med.kyoto-u.ac.jp/en/
www.ccii.med.kyoto-u.ac.jp/en/
December 15, 2025 at 6:14 AM
Prof Tasuku Honjo is now the Director of CCII, our new center in Kyoto University, dedicated to deciphering anti-tumor immunity and discovering the next generation of cancer immunotherapies.
www.ccii.med.kyoto-u.ac.jp/en/
www.ccii.med.kyoto-u.ac.jp/en/